A Stock Chart & Stats
$2350.00
$0.00(0.00%)
At close: 4:00 PM EDT
$2350.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1,911.01 - $3,081.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$926.20B
Enterprise Value$41.35B
Total Cash (Recent Filing)$1.76B
Total Debt (Recent Filing)$3.95B
Price to Earnings (P/E)34.4
Beta-0.19
Next Earnings
Nov 23, 2026EPS Estimate
32.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.09
Shares Outstanding281,928,860
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio9.44
Price to Book (P/B)6.14
Price to Sales (P/S)5.96
P/FCF Ratio35.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$3,449.25Price Target Upside46.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)126.09
Revenue Forecast (FY)$150.04B
Bulls Say, Bears Say
Bulls Say
Recurring Installed-base RevenueAgilent’s instruments create an installed base that supports repeat purchases of consumables, maintenance, services and software. This recurring pull-through can deepen customer relationships, raise switching costs and make revenue more resilient than reliance on one-time equipment sales alone.
Raised Growth And Earnings OutlookRaised full-year revenue and EPS guidance indicates that management sees demand and execution supporting continued expansion. The outlook also calls for more than 100 basis points of operating-margin growth excluding refunds, providing a constructive foundation for earnings over the next several quarters.
Strong Cash GenerationHigh free-cash-flow conversion gives Agilent meaningful capacity to fund research, product development, capital spending and shareholder returns. Strong cash generation also provides balance-sheet optionality, helping the company invest through market cycles without depending entirely on external financing.
Bears Say
Gross-margin CompressionThe sharp decline in gross margin raises questions about the durability of profitability and the company’s ability to preserve pricing power. If mix, pricing or cost pressures persist, lower gross profit per dollar of revenue could constrain operating leverage and reduce earnings upside.
Higher Debt Reduces FlexibilityHigher debt increases fixed financial commitments and reduces flexibility if operating conditions weaken. Although leverage remains moderate, additional borrowing can limit the funds available for acquisitions, innovation or shareholder returns and makes disciplined capital allocation more important.
Operating Cash-flow Conversion DragOperating cash flow consistently trailing accounting earnings suggests working-capital or timing effects that can make cash realization uneven. Even with strong free cash flow overall, weaker conversion may create quarter-to-quarter volatility and reduce confidence that reported earnings translate smoothly into available cash.
Agilent News
A FAQ
What was Agilent’s price range in the past 12 months?
Agilent lowest stock price was $1911.01 and its highest was $3081.00 in the past 12 months.
What is Agilent’s market cap?
Agilent’s market cap is $926.20B.
When is Agilent’s upcoming earnings report date?
Agilent’s upcoming earnings report date is Nov 23, 2026 which is in 23 days.
How were Agilent’s earnings last quarter?
Agilent released its earnings results on Aug 26, 2026. The company reported $30.435 earnings per share for the quarter, beating the consensus estimate of $27.955 by $2.48.
Is Agilent overvalued?
According to Wall Street analysts Agilent’s price is currently Undervalued.
Does Agilent pay dividends?
Agilent does not currently pay dividends.
What is Agilent’s EPS estimate?
Agilent’s EPS estimate is 32.44.
How many shares outstanding does Agilent have?
Agilent has 281,928,860 shares outstanding.
What happened to Agilent’s price movement after its last earnings report?
Agilent reported an EPS of $30.435 in its last earnings report, beating expectations of $27.955. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Agilent?
Currently, no hedge funds are holding shares in MX:A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Agilent Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3,449.25 (46.78% Upside)
$3,449.25 (46.78% Upside)
Blogger Sentiment
Bullish
MX:A Sentiment 62%
Sector Average 64%
Sector Average 64%
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Positive
20 days / 200 days
Momentum
22.89%
12-Months-Change
Fundamentals
Return on Equity
20.47%
Trailing 12-Months
Asset Growth
14.24%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Agilent
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.
A Company Deck
A Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum: solid top-line beats, meaningful margin expansion (noting some benefit from one-time tariff refunds), raised full-year guidance, robust cash generation, continued product and China momentum, and visible benefits from the Ignite transformation. Lowlights were largely timing, one-time refund effects, regional softness in pockets (Europe, parts of C&E) and near-term variability related to CDMO ramp timing and macro/cost pressures. On balance the positives substantially outweighed the negatives.View all MX:A earnings summariesA Revenue Breakdown
39.23% Life Sciences and Diagnostics Markets
41.85% Agilent CrossLab
18.91% Applied Markets
A Stock 12 Month Forecast
Average Price Target
$3,449.25
▲(46.78% Upside)